| Autor: |
Voicu, Victor, Diehm, Nicolas, Moarof, Igal, Parejo, Sarah, Badiqué, Florent, Burden, Andrea, Niedrig, David, Béchir, Markus, Russmann, Stefan |
| Zdroj: |
Pharmacogenomics; December 2023, Vol. 25 Issue: 1 p5-19, 15p |
| Abstrakt: |
Aim:Implementation of CYP2C19point-of-care (POC) pharmacogenetic (PGx) testing with personalized treatment recommendations. Methods:POC CYP2C19genotyping plus expert evaluation of risk factors for ischemic and bleeding events. Results:167 patients underwent PGx testing, 54 (32.3%) were CYP2C19loss of function carriers, and POC versus standard PGx analysis results for *2and *3variants matched in 100%. Antiplatelet therapy was adjusted in 44 patients (26.3%), but always required consideration of patient-specific factors. Conclusion:CYP2C19POC-PGx is reliable and offers clinically relevant advantages for immediate evidence-based adaptations of antiplatelet therapy, whereas in less acute cases conventional PGx testing can also have advantages. Antiplatelet therapy has become more complex, and implementation of PGx-based personalized antiplatelet therapy requires complementary expert knowledge. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
